Local liquid biopsy company Trovagene Inc. has inked a deal with Big Pharma AstraZeneca.
As part of the deal, the San Diego company will give AstraZeneca access to its Trovera urine circulating tumor DNA biomarker test and services.
Trovagene’s test will then be used in a study evaluating whether the combined use of urine and blood testing is as effective as tissue testing when identifying mutations in the EGFR gene (epidermal growth factor receptor).
"We're pleased to partner with AstraZeneca and to have our urine liquid biopsy test included in a trial designed to explore new and non-invasive ways to detect if patients have this EGFR mutation and may be appropriate for specific treatment options," said Bill Welch, CEO of Trovagene. "This agreement marks a major milestone for Trovagene."